Antithrombotic drugs help in the prevention or inhibition of thrombus by mimicking the role of antithrombin, a protein molecule produced in our body which helps in clotting. The protein molecule is produced by the liver, and among other benefits, has anti-inflammatory effects. Engineered recombinant antithrombin has gained clinical significant in recent years for the prevention of various peri-partum and peri-operative thromboembolic events or blood clots.
A notable development in the market has been the U.S. FDA approval of ATryn in 2009. The molecule, a recombinant Antithrombin, has been manufactured by rEVO Biologics and has been useful in treating patients suffering from hereditary antithrombin (AT) deficiency undergoing surgery or giving birth. However, the treatment is not yet approved for indications in patients suffering from hereditary antithrombin deficient. Several clinical studies and developments of novel targeted therapies are ongoing and boost the evolution of the Antithrombin market.
The report provides comprehensive insights into the key market dynamics, emerging trends, opportunities, research and development activities, regulatory landscape, and competitive dynamics. The study is an indispensable guide for all market participants exploring imminent investment pockets in various regions as they can capitalize on lucrative market avenues.
This report gives readers a comprehensive overview of the Antithrombin (recombinant) Market:
Managing the right level of the coagulation protein antithrombin in human body is essential. The deficiency of the protein may be fatal and is prominent in case of patients suffering from an inherited deficiency, a genetic rare disease. The growing prevalence of this disease, both among men and women, is a key factor propelling the demand for antithrombin drugs and therapies. The recent FDA approval of recombinant antithrombins in major region has increasingly boosted the market. The protein molecules have also gained importance to boost the levels of Antithrombin in patients. This deficiency is attributed to clinical conditions prevalent in patients affected by liver failure, metastatic tumors, severe trauma, and nephritic syndrome. Moreover, patients undergoing heparin therapy and chemotherapy may also suffer from antithrombin deficiency. These factor are expected to catalyze the market growth over the forecast period.
However, the limited efficacy of antithrombin to improve neonatal outcomes is likely to impede the market to an extent. Furthermore, ATryn, the recently approved recombinant antithrombin by U.S. FDA, is found to have contraindications in patients who have hypersensitivity to goat milk proteins. Nevertheless, recent advances in clinical studies in evaluating the potential of recombinant antithrombins in prolonging gestation so as to improve maternal and neonatal outcomes have opened up exciting opportunities for market players.
Get accurate market forecast and analysis on the Antithrombin (recombinant) Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4500
The major regional markets for antithrombin are North America, Europe, and Asia Pacific. Of these, North America is a prominent market and is trailed by Europe. The substantial growth in these regional markets is attributed to the early adoption of recombinant antithrombins in preventing various clinical conditions caused by the prevention of blood clots.
However, Asia Pacific is projected to witness a robust demand for recombinant antithrombins. This regional market is chiefly driven by the surge in demand from the countries such as India and China. In addition, the growing incidence of various cardiovascular diseases is expected to propel the demand for recombinant antithrombins in various countries of Asia Pacific.
Key companies operating in the antithrombin (recombinant) market include rEVO Biologics Inc., Ovation Pharmaceuticals, and GTC Biotherapeutics Inc. In the coming years, the market is expected to witness several large pharmaceutical companies making a foray in the biotechnology segment. They intend to make intensive research and development in biotechnology to gain a foothold in the market in various regions. This is likely to intensify the competition in the global antithrombin (recombinant) market over the forecast period.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453